How Anti-Diabetic Products Help in Managing Blood Sugar Levels Effectively

Anti-diabetic products based on well-studied oral and injectable agents help people with type 2 diabetes achieve and maintain effective blood sugar control, especially when lifestyle measures alone are not sufficient. Evidence-based combinations of sulfonylureas, DPP-4 inhibitors, and SGLT2 inhibitors help personalise therapy, achieve HbA1c targets (<7%), and reduce long-term complications such as cardiovascular and kidney disease.

Growing diabetes burden and need for control

India has one of the highest diabetes burdens globally, with an estimated 11–11.4% of adults living with diabetes and a substantial additional proportion with prediabetes. This high prevalence translates into increased risks of cardiovascular disease, kidney failure, neuropathy, and vision loss if blood sugar is not adequately controlled over time.

For many people with type 2 diabetes, lifestyle interventions such as diet modification and physical activity, while essential, do not by themselves maintain glycated haemoglobin (HbA1c) within target ranges (typically <7% as per ADA guidelines). This makes evidence-based anti-diabetic medications important for long-term management, alongside lifestyle measures,.

How key anti diabetic drug classes work

Anti-diabetic products work through distinct mechanisms that can be combined to stabilise fasting and post-prandial glucose levels and reduce glycaemic variability. Major oral drug classes commonly used in India and reflected in portfolios of leading manufacturers include:

• Biguanides (Metformin): Metformin decreases hepatic glucose production, reduces intestinal glucose absorption, and improves peripheral insulin sensitivity, making it the standard first-line pharmacologic therapy in type 2 diabetes.​
• Sulfonylureas (e.g., glimepiride, gliclazide, glibenclamide): These agents stimulate pancreatic beta cells to release more insulin, thereby lowering blood glucose, particularly fasting levels, but require careful dosing because of hypoglycaemia risk.
• DPP-4 inhibitors (e.g., vildagliptin, sitagliptin, linagliptin, teneligliptin): By inhibiting dipeptidyl peptidase-4, these drugs increase incretin hormones, which enhance glucose-dependent insulin secretion and suppress glucagon, typically with a neutral effect on weight and lower hypoglycaemia risk.
• SGLT2 inhibitors (e.g., dapagliflozin, remogliflozin): These agents inhibit sodium–glucose co-transporter-2 in the kidney, promoting urinary glucose excretion and thereby lowering blood sugar while often offering additional benefits on body weight and blood pressure.

Collectively, these antidiabetic drugs allow physicians to sequence and combine therapies according to disease stage, comorbidities, and patient tolerance.

Role of fixed-dose combinations in effective control

Fixed-dose combinations (FDCs) that pair or group two or three anti diabetic molecules in a single tablet are widely used in India to simplify treatment and improve adherence. These products often combine metformin with sulfonylureas, DPP-4 inhibitors, SGLT2 inhibitors, or thiazolidinediones to target complementary mechanisms.

Key benefits of rational FDCs in type 2 diabetes management include:

• Mechanistic synergy: Combinations such as metformin plus a DPP-4 inhibitor (e.g., metformin + vildagliptin) link insulin sensitisation with glucose-dependent insulin secretion, improving overall glycaemic control compared with monotherapy.
• Triple-agent control: Regimens like dapagliflozin + metformin + vildagliptin or dapagliflozin + glimepiride + metformin combine SGLT2 inhibition, insulin sensitisation, and either insulin secretion enhancement or incretin-based action, enabling stronger HbA1c reduction in patients inadequately controlled on dual therapy.
• Adherence and convenience: Single-tablet FDCs reduce pill burden, which is especially important for people with multiple non-communicable diseases such as hypertension and dyslipidaemia alongside diabetes.mankindpharma+1​

.

Innovation and chronic-care focus in industry

Leading Indian pharmaceutical manufacturers, including Mankind Pharma, have strategically expanded their chronic therapy portfolios, covering cardiovascular, anti-diabetic, and related metabolic segments to address the country’s shifting disease burden. In its FY24 annual report, Mankind Pharma highlights chronic therapies (including anti-diabetic drugs) as a key growth driver, with chronic share rising to about 36% of domestic revenue and dedicated speciality divisions for cardiovascular and diabetes care.

  Mankind Pharma has also successfully completed the Phase I clinical trial for a GPR-119–targeted new chemical entity intended to address obesity and diabetes, reflecting an innovation pipeline focused on next-generation metabolic therapies. Partnerships for long-acting insulins and other chronic-care biologics further support integrated management for patients who eventually require injectable anti diabetic products in addition to oral agents.

Integrating anti diabetic medication into holistic care

While anti diabetic products are essential, they are most effective when embedded in a comprehensive care plan that includes lifestyle, monitoring, and management of comorbidities. National and international guidance emphasises:

• Lifestyle optimisation: Calorie-appropriate, balanced nutrition; regular physical activity; weight management; smoking cessation; and moderation of alcohol are foundational measures that enhance the effectiveness of pharmacotherapy.
• Regular monitoring and review: Periodic HbA1c tests, home blood glucose monitoring where indicated, and structured follow-up visits allow timely adjustment of antidiabetic drugs to prevent both hyperglycaemia and hypoglycaemia.
• Comprehensive risk reduction: Because type 2 diabetes substantially increases cardiovascular risk, concurrent management of blood pressure and lipids with appropriate antihypertensives and statins is crucial in addition to glycaemic control.

By using evidence-based combinations of metformin, sulfonylureas, DPP-4 inhibitors, SGLT2 inhibitors, thiazolidinediones, and related agents—often as fixed-dose combinations—within such a holistic framework, clinicians can help patients manage blood sugar levels more effectively and reduce the long-term complications associated with type 2 diabetes

Designed by Freepik